Ginkgo Bioworks Holdings, Inc. (DNA) research
Ginkgo Bioworks Holdings, Inc.- Sector
- Life Sciences Tools & Services
- Last price
- $9.37
- As of
Ginkgo Bioworks Holdings, Inc. (DNA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
As of . Source: SEC EDGAR filings for DNA. Method and limitations.
Share the DNA intelligence card
See DNA live in the terminal
Track DNA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live DNA terminal, freeActive signals for DNA
- highCONSENSUS_BUY
4 tracked funds increased DNA this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +437% to DNA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 51% of DNA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +83% to DNA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +51% to DNA (2026Q2)
FREE, NO ACCOUNT
Every signal on DNA, as it fires
You are seeing 5 of 25 signals recorded on DNA since 2026-05-31.
The five above landed across 2 days. The other 20 were recorded on 4 other days. 20 of the 25 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DNA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 37611X209 · 2026Q2 | $35.4M | 0.10% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 37611X209 · 2026Q2 | $6.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 37611X209 · 2026Q2 | $5.3M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 37611X209 · 2026Q2 | $1.5M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 37611X209 · 2026Q2 | $1.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 37611X209 · 2026Q2 | $599K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DNA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
DNA against its peers
DNA's operating margin of -185.3% ranks in the 23rd percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | DNA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 170M USD | 1.2B USD | 25 | 25 |
| Gross margin | n/a | 55.5% | n/a | 13 |
| Operating margin | -185.3% | -9.5% | 23 | 23 |
| Net margin | -183.8% | -6.8% | 21 | 25 |
| Return on equity | -61.5% | -7.5% | 18 | 24 |
| P / E | n/a | 43.1x | n/a | 10 |
Peers (25): OABI, PACB, CTKB, MLAB, MRVI, CDXS, FTRE, MXCT, SEER, ABCL, ADPT, SHC, BRKR, RGEN, TXG, AVTR, TEM, TECH, CRL, MEDP, MTD, ILMN, WAT, A, IQV. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (DNA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more DNA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to DNAand get the insider, 13F, options, and confluence read in one view.